Skip to content
Open in App
Adlai Nortye ADR logo

Adlai Nortye ADR

web2

Adlai Nortye is a clinical stage biopharmaceutical company developing experimental cancer thera...

Symbol ยท ANL
Company profile

About

Adlai Nortye is a clinical stage biopharmaceutical company developing experimental cancer therapies, with American depositary shares representing ownership interests in its listed holding company. Its research focuses on treatments targeting cancer signaling pathways and mechanisms that influence immune responses to tumors. Its development portfolio includes AN9025, an oral RAS inhibitor, AN4035, an antibody drug conjugate, and AN8025, an investigational immunotherapy. The company conducts clinical development activities involving patients in multiple jurisdictions and collaborates with research and pharmaceutical organizations. Its American depositary shares trade on Nasdaq under ANL, while its investigational treatments remain subject to clinical testing and regulatory evaluation.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ANL
Expert coverage

Adlai Nortye ADR profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment